Logo

Alexion's Ultomiris (ravulizumab) Receives EC's Approval for Expanded Use to Treat Paroxysmal Nocturnal Haemoglobinuria

Share this

Alexion's Ultomiris (ravulizumab) Receives EC's Approval for Expanded Use to Treat Paroxysmal Nocturnal Haemoglobinuria

Shots:

  • The approval is based on the P-III trial that evaluates Ultomiris (q4w/q8w) vs Soliris in children & adolescents aged ≤18yrs. with PNH
  • The interim result showed that the therapy was effective in achieving C5 complement inhibition @26wks. & demonstrated safety & efficacy profile with reduced dosing frequency- no treatment-related SAEs & no patients discontinued treatment were observed during the primary evaluation period or experienced breakthrough hemolysis
  • The therapy is approved in the US for adults & children aged ≥1mos. with PNH & in the EU for adults & children who experience hemolysis with clinical symptoms & who are clinically stable after being treated with Soliris for the past 6mos.

  | Ref: AstraZeneca | Image: Stat News

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions